Food and Drug Administration about unapproved and potentially dangerous versions of the popular GLP-1 drugs
According to Gruchlik et al, GHK-Cu decreases TNF-alpha-dependent IL-6 secretion in fibroblasts, and is preferable for use on the skin to corticosteroids or non-steroidal anti-inflammatory drugs, which have greater side effects [9]
The FDA flagged a number of items that it claims are misleading, including theres a lack of clinical data to support the superiority of Ozempic relative to other GLP-1s, and the letter takes aim at small details in the ad, from comedic devices to the color of shirts
But I think I think this is why conversations like this are so [00:32:00] important because if we start voicing now that we want to see that research, perhaps we can get it sooner
If you stop taking your medication and then restart it, you may experience side effects similar to what you experienced when you first started taking it